Skip to content

Different diuretic regimes and long-term outcomes in heart failure with mildly reduced ejection fraction

Aug 2026 · Current Medical Research and Opinion · Vol 42, pp. 1697 - 1708 · 0 citations · 26 references
Medicine

TL;DR

Thiazide-only therapy was associated with the lowest mortality, while loop and combined diuretic therapy were linked to increased mortality and HF-rehospitalization, and Randomized trials investigating long-term diuretic therapy in HFmrEF patients are needed.

Abstract

Abstract Background & Objective Diuretics are commonly prescribed for patients with heart failure (HF), yet prognostic data in HF with mildly reduced ejection fraction (HFmrEF) remain limited. This study investigates the prognostic impact of thiazide and loop diuretics in HFmrEF. Methods Consecutive HFmrEF patients hospitalized at the University Medical Centre Mannheim between 2016 and 2022 were retrospectively included (HARMER registry, clinicaltrials.gov identifier: NCT05603390) and stratified by diuretic therapy at discharge: none (N), thiazide-only (T), loop diuretic-only (L), or combined diuretic therapy (T + L). The primary endpoint was all-cause mortality at 30 months (median follow-up), secondary endpoint was HF-related rehospitalization. Results Among 2,109 HFmrEF patients discharged alive, 43% received no diuretics, 9% thiazides only, 40% loop diuretics only, and 9% combined diuretic therapy. Thiazide-only patients had the lowest of long-term all-cause mortality (11%) compared to no diuretics (20%), while patients with loop (39%), and combined diuretic therapy (48%) had higher long-term mortality rates (log-rank p = 0.001). HF-rehospitalization rates followed a similar pattern (N: 5% and T: 7% vs. L: 21% and L + T: 31%, p = 0.001). After multivariable adjustment, thiazide-only therapy remained associated with lower mortality (HR = 0.515, p = 0.009), while loop and combined diuretic therapy were associated with increased mortality (L: HR = 1.299, p = 0.031; T + L: HR = 1.702, p = 0.001) and HF-rehospitalization (L: HR = 1.998, p = 0.001; T + L: HR = 2.535, p = 0.001). Conclusion In HFmrEF, thiazide-only therapy was associated with the lowest mortality, while loop and combined diuretic therapy were linked to increased mortality and HF-rehospitalization. Randomized trials investigating long-term diuretic therapy in HFmrEF patients are needed. GRAPHICAL ABSTRACTFlowchart of patient selection, Kaplan-Meier survival curves for diuretic therapies, and hazard ratio analysis for heart failure outcomes.The figure displays a flowchart, Kaplan-Meier survival curves, and a hazard ratio table related to a study on heart failure with mildly reduced ejection fraction. The flowchart begins with 2,184 patients, excluding 75 deceased during admission, resulting in 2,109 eligible patients split into groups: No diuretic (896), Thiazide-only (195), Loop diuretic (835), and Thiazide + Loop diuretic (183). The survival curve shows all-cause mortality over 30 months, with significant differences among groups (p = 0.001). Hazard ratios indicate thiazide-only therapy has the lowest mortality risk (HR=0.529), while loop diuretics and combinations show higher risks.

View source

Similar papers

Open access Sep 2026

Eficacy of Dapagliflozin in Patients with Heart Failure with Preserved Ejection Fraction: A Randomized Controlled Trial Study

Heart failure (HF) with preserved ejection fraction (HFpEF) is a major clinical difficulty caused by the existence of restricted therapeutic alternatives. Sodium-glucose cotransporter-2 inhibitors, including dapagliflozin, have demonstrated possible benefits in the therapy of HF. A randomized controlled...

Saurav P. Singhvi, V. Selvaraj, Naveena Dhandapani et al. · 0 citations
Sep 2026

Urinary sodium, baseline loop diuretic dose, and short-term outcomes in ambulatory worsening heart failure: The NaU/F Index.

BACKGROUND Worsening heart failure (WHF) carries high short-term morbidity and mortality. Spot urinary sodium (NaU) is increasingly used to assess diuretic response but does not account for chronic loop diuretic exposure. OBJECTIVES To determine whether a urinary sodium-to-furosemide index (NaU/F) improves short-term...

L. Burgos, M. A. De Bortoli, R. Barovila et al. · 0 citations
Open access Aug 2026

Heart Failure With Reduced Ejection Fraction and SGLT2 Inhibitors- Clinical Outcomes, Adverse Events, and Comorbidities Over Three Years: A Retrospective Cohort Study

SGLT2 inhibitor use in heart failure with reduced ejection fraction was associated with significantly improved long-term survival and a substantial reduction in heart failure and acute coronary syndrome hospitalizations, without increased risk of AKI or UTI.

Jonathan Zawadzki, Ronit Kar, G. Bailey et al. · 0 citations
Open access 2026

Implementation of optimal medical therapy in patients hospitalized for heart failure

Although ACEI/ARB/ARNI therapy showed high adherence, BBs and MRAs were less frequently used, and SGLT2Is were under-prescribed, greater efforts are needed to improve adherence to ESC recommendations at discharge.

Andrijana Stošić, Marija Polovina · 0 citations
Open access Sep 2026

Observational study on initiation of dapagliflozin in heart failure with reduced ejection fraction in the United Kingdom

Patients receiving dapagliflozin recorded low levels of discontinuation, suggesting high tolerability, and had fair-to-good QoL throughout the study, indicating good patient experience during HFrEF treatment including dapagliflozin.

Steven Coombs, Angela Tithecott, C. Thiebaud et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.